JAK2

Chr 9ADSomatic

Janus kinase 2

Also known as: JTK10

This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

Primary Disease Associations & Inheritance

{Budd-Chiari syndrome, somatic}MIM #600880
Erythrocytosis, somaticMIM #133100
Leukemia, acute myeloid, somaticMIM #601626
Myelofibrosis, somaticMIM #254450
Polycythemia vera, somaticMIM #263300
Thrombocythemia 3MIM #614521
ADSomatic
785
ClinVar variants
17
Pathogenic / LP
0.65
pLI score
12
Active trials
Clinical SummaryJAK2
Population Constraint (gnomAD)
Moderately constrained gene (pLI 0.65) — some intolerance to loss-of-function variants.
📋
ClinVar Variants
17 Pathogenic / Likely Pathogenic· 258 VUS of 785 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
Some data sources returned errors (1)

clinvar: Error: NCBI fetch failed: 429 https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.34LOEUF
pLI 0.654
Z-score 5.66
OE 0.21 (0.140.34)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.90Z-score
OE missense 0.90 (0.830.96)
518 obs / 578.6 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.21 (0.140.34)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.90 (0.830.96)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.11
01.21.6
LoF obs/exp: 13 / 60.6Missense obs/exp: 518 / 578.6Syn Z: -1.21

ClinVar Variant Classifications

785 submitted variants in ClinVar

Classification Summary

Pathogenic11
Likely Pathogenic6
VUS258
Likely Benign89
Benign16
Conflicting3
11
Pathogenic
6
Likely Pathogenic
258
VUS
89
Likely Benign
16
Benign
3
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
11
0
11
Likely Pathogenic
1
2
3
0
6
VUS
7
220
27
4
258
Likely Benign
0
4
32
53
89
Benign
0
0
13
3
16
Conflicting
3
Total82268660383

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

JAK2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

JANUS KINASE 2; JAK2
MIM #147796 · *

{Budd-Chiari syndrome, somatic}

MIM #600880

Molecular basis of disorder known

Erythrocytosis, somatic

MIM #133100

Molecular basis of disorder known

Leukemia, acute myeloid, somatic

MIM #601626

Molecular basis of disorder known

Myelofibrosis, somatic

MIM #254450

Molecular basis of disorder known

Polycythemia vera, somatic

MIM #263300

Molecular basis of disorder known

Thrombocythemia 3

MIM #614521

Molecular basis of disorder known

Autosomal dominantSomatic mutation
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
The MPL mutation.
Guglielmelli P et al.·Int Rev Cell Mol Biol
2021Review
Polycythaemia vera.
Harrison CN et al.·Nat Rev Dis Primers
2025Review
Plaque erosion risk and JAK2 V617F variant.
Wang S et al.·Eur Heart J
2025
Familial MPN Predisposition.
Tashi T et al.·Curr Hematol Malig Rep
2017Review
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

BCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White CellsBlasts More Than 5 Percent of Bone Marrow Nucleated Cells

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

RECRUITING
NCT03801434Phase PHASE2William ShomaliStarted 2019-11-15
Ruxolitinib
Myelofibrosis

Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels

ACTIVE NOT RECRUITING
NCT07342712First Affiliated Hospital of Zhejiang UniversityStarted 2025-08-01
Myeloproliferative NeoplasmPolycythemia VeraEssential Thrombocythemia

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes

RECRUITING
NCT06361641Phase NAUniversity Hospital, AngersStarted 2024-05-29
Monocytes signatures in myeloproliferative neoplasms at diagnosis
Myelofibrosis

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

RECRUITING
NCT06122831Phase PHASE1, PHASE2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Started 2023-12-12
TQ05105 TabletsTQB3617 Capsules
Insulin ResistanceObesity & OverweightEnergy Metabolism

Effects of Ketone Bodies on Insulin Sensitivity

RECRUITING
NCT07359625Phase NAUniversity of AarhusStarted 2025-12-02
Growth Hormone, HumanOral ketone supplement (KetoAid®, KE4)Saline infusion (placebo)
Myelofibrosis

Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

RECRUITING
NCT06605586Phase PHASE1, PHASE2Stichting Hemato-Oncologie voor Volwassenen NederlandStarted 2025-02-20
Tasquinimod
Myelofibrosis,MF

Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia

NOT YET RECRUITING
NCT07394153Phase PHASE2Grupo Español de Enfermedades Mieloproliferativas Crónicas PH NegativasStarted 2026-03
Pacritinib
T-cell LymphomaGraft Versus Host DiseaseLymphoma, T-Cell

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

RECRUITING
NCT07356245Phase PHASE2Jonathan BrammerStarted 2026-02-01
RuxolitinibPositron emission tomography-computed tomographyBone Marrow Biopsy
Myeloproliferative DiseaseGermline Mutation

Unveiling the Germline Predisposition to Myeloproliferative Neoplasms

RECRUITING
NCT07204392Fondazione IRCCS Policlinico San Matteo di PaviaStarted 2022-06-27
Polycythemia VeraEssential ThrombocythaemiaMyelofibrosis

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

NOT YET RECRUITING
NCT06923670Phase NAFondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2025-05-21
NGS testingNGS analysis for mutations in genes involved in familial predisposition to hematological malignancies
E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic SyndromeVEXASVexas Syndrome

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

RECRUITING
NCT06538181Phase PHASE1Washington University School of MedicineStarted 2025-02-13
Pacritinib
Aplastic AnemiaTPO Receptor Agonists

Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia

RECRUITING
NCT06613880Phase PHASE2Institute of Hematology & Blood Diseases Hospital, ChinaStarted 2024-10-24
standard IST combined with Romiplostim N01